Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Erasca, Inc. - Common Stock (NQ:ERAS)

13.25 -0.16 (-1.19%)
Streaming Delayed Price Updated: 1:54 PM EDT, Jun 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,666,710
Open 13.32
Bid (Size) 13.24 (100)
Ask (Size) 13.27 (300)
Prev. Close 13.41
Today's Range 13.00 - 13.79
52wk Range 1.210 - 24.28
Shares Outstanding 151,043,118
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bragar Eagel & Squire, P.C. is Investigating Erasca, Inc. (NASDAQ:ERAS) on Behalf of Erasca Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗
This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+269.1%
+269.1%
1 Month
+26.9%
+26.9%
3 Month
-15.0%
-15.0%
6 Month
+301.5%
+301.5%
1 Year
+712.9%
+712.9%

More News

Read More
News headline image
ERAS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Erasca, Inc.
From Kirby McInerney LLP
Via Business Wire
Erasca (NASDAQ:ERAS) Beats Q1 Estimates on Promising ERAS-0015 Data ↗
Via Chartmill
News headline image
ERASCA INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Erasca, Inc. on Behalf of Erasca Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally ↗
Via The Motley Fool
News headline image
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference ↗
Via MarketBeat
News headline image
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ERAS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
ERASCA INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Erasca, Inc. on Behalf of Erasca Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗
Via The Motley Fool
Topics Initial Public Offering
News headline image
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ERASCA, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
From Kirby McInerney LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
From Pomerantz LLP
Via GlobeNewswire
News headline image
ERAS Investors Have Opportunity to Join Erasca, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial ↗
Via The Motley Fool
Topics Stocks
Here are the top movers in Tuesday's session. ↗
Via Chartmill
Which stocks are experiencing notable movement on Tuesday? ↗
Via Chartmill
Gapping stocks in Tuesday's session ↗
Via Chartmill
Top movers in Tuesday's pre-market session ↗
Via Chartmill

Frequently Asked Questions

Is Erasca, Inc. - Common Stock publicly traded?
Yes, Erasca, Inc. - Common Stock is publicly traded.
What exchange does Erasca, Inc. - Common Stock trade on?
Erasca, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Erasca, Inc. - Common Stock?
The ticker symbol for Erasca, Inc. - Common Stock is ERAS on the Nasdaq Stock Market
What is the current price of Erasca, Inc. - Common Stock?
The current price of Erasca, Inc. - Common Stock is 13.25
When was Erasca, Inc. - Common Stock last traded?
The last trade of Erasca, Inc. - Common Stock was at 06/10/26 01:54 PM ET
What is the market capitalization of Erasca, Inc. - Common Stock?
The market capitalization of Erasca, Inc. - Common Stock is 2.00B
How many shares of Erasca, Inc. - Common Stock are outstanding?
Erasca, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.